The US FDA has awarded Biosyngen’s IND for the T-cell receptor therapy, BRL03, t...
While the angst over another rise in Covid cases is understandable, there’s some...
Crinetics Pharmaceuticals announced its experimental drug for acromegaly succeed...
In this issue: Digital jobs in UK life sciences, generative AI changes drug disc...
The Arena International Outsourcing in Clinical Trials UK and Ireland discussed ...
The company expects a further survival readout in Q4 2023, with plans for a seco...
Eloxx has submitted an IND for a pivotal trial to study its Alport syndrome ther...
In 2022, global regulatory authorities awarded a record ten review designations ...
Otsuka Pharmaceutical has entered a partnership with ShapeTX for the development...
The UK NICE has recommended Eli Lilly’s tirzepatide for the treatment of adult p...
The European Commission granted expanded indication approval for Merck’s Ebola v...
Biocytogen and Myricx Bio have signed an antibody evaluation, option and licence...
The PD-1/PD-L1 inhibitor landscape is at the precipice of change with the approv...
Brian Wallach, ALS advocate: “We know that these treatments are not cures, but t...
“The idea that these supplements would be marketed in a way that people have a h...
Swiss drugmaker Novartis’ research and development hub has a new name — and a ne...
